| Predicate |
Object |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0034
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4745
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D471-04 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4745
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00 |
| filingDate |
2009-02-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate |
2011-04-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
JP-2011511073-A |
| titleOfInvention |
Treatment of bladder disease with TLR7 activator |
| abstract |
The present invention provides methods for the treatment of superficial bladder cancer and inflammatory diseases of the bladder using certain Toll-like receptor (TLR) agonists. The method was formulated to optimize the concentration of a synthetic TLR7 agonist in the bladder mucosa relative to blood, modified to optimize the concentration of the synthetic TLR7 agonist in the bladder mucosa relative to blood, or Administration of a synthetic TLR7 activator (agonist) co-administered with other treatments to optimize the concentration of the synthetic TLR7 agonist in the bladder mucosa relative to blood. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2017502084-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2017507912-A |
| priorityDate |
2008-02-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |